Elicio Therapeutics, Inc.
$12.2
▼
-0.09%
2026-04-21 06:37:00
elicio.com
NCM: ELTX
Explore Elicio Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$224.43 M
Current Price
$12.2
52W High / Low
$14.93 / $4.7
Stock P/E
—
Book Value
$0.09
Dividend Yield
—
ROCE
-210.11%
ROE
817.92%
Face Value
—
EPS
$-2.58
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
33
Beta
1.88
Debt / Equity
887.04
Current Ratio
2.38
Quick Ratio
2.38
Forward P/E
-7.25
Price / Sales
—
Enterprise Value
$182.67 M
EV / EBITDA
-4.87
EV / Revenue
—
Rating
Strong Buy
Target Price
$17.5
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Lite Strategy, Inc. | $1.19 | — | $42.54 M | 0% | -103.09% | -76.38% | $9 / $0.95 | $2.23 |
| 2. | ArriVent BioPharma, Inc. | $31.39 | — | $1.31 B | — | -57.79% | -58.88% | $30.72 / $16.1 | $7.24 |
| 3. | BioAtla, Inc. | $5.69 | — | $7.61 M | — | 732.7% | 543.76% | $71.5 / $3.92 | $-0.6 |
| 4. | AbCellera Biologics Inc. | $3.91 | — | $1.22 B | — | -15.72% | -14.47% | $6.51 / $1.94 | $3.22 |
| 5. | Inhibikase Therapeutics, Inc. | $1.81 | — | $238.98 M | — | -30.85% | -36.04% | $2.37 / $1.33 | $1.02 |
| 6. | Grace Therapeutics, Inc. | $4.59 | — | $71.03 M | — | -23.81% | -10.22% | $5.18 / $2 | $4.19 |
| 7. | Lyell Immunopharma, Inc. | $24.89 | — | $559.6 M | — | -69.37% | -86.98% | $45 / $7.65 | $11.68 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -8.84 M | -8.04 M | -9.68 M | -10.74 M | -13.48 M | — |
| Net Profit | -7.72 M | -10.08 M | -10.56 M | -11.21 M | -14 M | — |
| EPS in Rs | -0.42 | -0.55 | -0.57 | -0.61 | -0.76 | -1.39 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -37.3 M | -44.99 M | -35.74 M | -23.73 M |
| Net Profit | -39.57 M | -51.9 M | -35.2 M | -28.21 M |
| EPS in Rs | -2.15 | -2.82 | -1.91 | -1.53 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 25.86 M | 28.18 M | 27.15 M | 22.66 M |
| Total Liabilities | 24.23 M | 39.49 M | 15.77 M | 124.81 M |
| Equity | 1.64 M | -11.31 M | 11.37 M | -102.14 M |
| Current Assets | 19.31 M | 20.69 M | 16.35 M | 10.72 M |
| Current Liabilities | 8.11 M | 11.52 M | 9.76 M | 6.87 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -36.95 M | -37.07 M | -32.69 M | -22.18 M |
| Investing CF | -0.02 M | -0.08 M | -0.03 M | -0.65 M |
| Financing CF | 36.7 M | 42.32 M | 38.61 M | 21.2 M |
| Free CF | -36.97 M | -37.16 M | -32.76 M | -22.83 M |
| Capex | -0.02 M | -0.09 M | -0.07 M | -0.65 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 23.75% | -47.46% | -24.77% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-06-02 | 1:0.1 |